Table 1.
Prospective HSC isolation
| HSPC population | Transplanted cells | Assay/model | HSCs (%) | References |
|---|---|---|---|---|
| Murine | ||||
| Thy-1low/Sca-1+/Lin− | 30 | Competitive | 1.5–3 | Spangrude et al. 1988 |
| KSL | Limiting dilutions | Competitive | 3–7 | Okada et al. 1992; Bryder et al. 2006 |
| Thy-1low KSL | 5–10 | Competitive | 10–20 | Morrison and Weissman 1994 |
| CD34− KSL | 1 | Competitive | 21 | Osawa et al. 1996 |
| SP Rholow/CD45mid/Lin− | 1 | Sublethal W-41 | 42/33 | Uchida et al. 2003; Dykstra et al. 2006 |
| SP CD201+ | 10 | Competitive | >10 | Balazs et al. 2006 |
| CD150+/CD48−/CD41− KSL | 1 | Competitive | 47 | Kiel et al. 2005 |
| CD150+/CD48−/CD49blow KSL | 1 | Sublethal W-41 competitive | 29 | Benveniste et al. 2010 |
| CD150+/CD48−/CD201+/CD45+ | 1 | Sublethal W-41 | 43 | Kent et al. 2009 |
| Human | ||||
| CD34+/CD38−/Lin− | Limiting dilutions | NOD/SCID | <1 | Bhatia et al. 1997 |
| CD34+/CD38−/CD90+/CD45RA−/Lin− | Limiting dilutions | Sublethal NSG | 5 | Majeti et al. 2007; Notta et al. 2011 |
| Rholow/CD49f+/CD34+/CD38−/CD90+/CD45RA−/Lin− | 1 | Sublethal NSG | 15 | Notta et al. 2011 |
HSPC, hematopoietic stem or progenitor cell; KSL, CD117+, Sca-1+, and Lin− cells; SP, side population; Rho, Rhodamine123; W-41, mouse line with homozygous KitW-41J/KitW-41J mutation; NOD/SCID, nonobese diabetic/severe combined immune deficiency mouse line; NSG, NOD/SCID/Il2 γ-chain knockout mouse line; competitive, transplantation in lethally irradiated recipients with “competitor-recipient” HSPCs.